Drug

Sisram Medical's Profhilo Facial Registration Accepted by NMPA – BDDE‑Free Hyaluronic Acid Biostimulator Poised for China's Aesthetics Market
Market approval filingsMedical aesthetics

Sisram Medical’s Profhilo Facial Registration Accepted by NMPA – BDDE‑Free Hyaluronic Acid Biostimulator Poised for China’s Aesthetics Market

Sisram Medical Ltd. (HKG: 1696) announced that the registration application for the facial indication of Profhilo, its high‑concentration sodium hyaluronate injectable, was formally accepted in September 2026 by China's National…

EyePoint's DURAVYU Misses Primary Endpoint in Phase III LUCIA Trial for Wet AMD – Non‑Inferiority vs. Aflibercept Not Achieved; Key Secondary Endpoints Met

EyePoint’s DURAVYU Misses Primary Endpoint in Phase III LUCIA Trial for Wet AMD – Non‑Inferiority vs. Aflibercept Not Achieved; Key Secondary Endpoints Met

Eli Lilly's Omvoh Delivers First One‑Year Phase 3 Readout in Pediatric Ulcerative Colitis – 50 % Clinical Remission at Week 52 in SHINE‑2

Eli Lilly’s Omvoh Delivers First One‑Year Phase 3 Readout in Pediatric Ulcerative Colitis – 50 % Clinical Remission at Week 52 in SHINE‑2

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Walvax Biotech Wins Jordan FDA Approval for 13‑Valent Pneumococcal Vaccine
Product approvalsSHE: 300142

Walvax Biotech Wins Jordan FDA Approval for 13‑Valent Pneumococcal Vaccine

Northeast Pharma Secures NMPA Approval for DCTY0801 Injection Targeting EGFRvIII‑Positive Brain Gliomas
CAR-TClinical trial approval / initiation

Northeast Pharma Secures NMPA Approval for DCTY0801 Injection Targeting EGFRvIII‑Positive Brain Gliomas

InnoCare, Zenas, Orelabrutinib: $2 B Licensing Deal Fuels MS Therapeutic Pipeline
Auto-immuneHKG: 9969

InnoCare, Zenas, Orelabrutinib: $2 B Licensing Deal Fuels MS Therapeutic Pipeline

Hengrui, SHR‑4298, RAS: China Approves Two Novel Anti‑Tumor Drugs for Clinical Trials
CancerClinical trial approval / initiation

Hengrui, SHR‑4298, RAS: China Approves Two Novel Anti‑Tumor Drugs for Clinical Trials

Show More